Heparin-induced thrombocytopenia (HIT) is a syndrome caused by platelet-activating antibodies that recognize complexes of platelet factor 4 (PF4) and heparin. Thrombocytopenia is the most common clinical feature of HIT. HIT can be considered as a hypercoagulable state, with a high risk of thrombosis. Another feature of HIT is an acute systemic reaction that characteristically begins 5–30 min after receiving an intravenous bolus of unfractionated heparin, such as is commonly given for hemodialysis (HD). Here we present 4 patients who developed acute HIT at or near the start of their chronic HD. All patients were anticoagulated with the low-molecular-weight heparin, nadroparin, for HD. Three of our patients underwent surgery approximately 1–2 weeks before developing HIT. All patients presented with an acute systemic reaction during HD. All patients were treated and further dialyzed with lepirudin. Under this treatment we observed a quick recovery of the platelet count, and patients remained symptom-free. Antibodies against the PF4-heparin complex were detected with a combination of a ‘quick test’ and an enzyme-linked immunosorbent assay test. The likelihood of having HIT previous to the detection of antibodies was estimated with the pre-test probability score criteria. The tests for PF4-heparin antibodies remained positive for an average of 165 days. Three patients underwent a rechallenge with nadroparin after disappearance of the HIT antibodies in their serum. All 3 remained symptomless when they were further hemodialyzed on nadroparin. Our observations indicate that nadroparin can be successfully reintroduced for HD anticoagulation once the patient’s HIT antibodies have disappeared.

Keywords:
Heparin-induced thrombocytopenia, PF4-heparin antibodies, Hemodialysis
1.
Warkentin TE, Greinacher A (eds): Heparin-Induced Thrombocytopenia, ed 3. New York, Dekker, 2004.
2.
Popov D, Zarrabi MH, Foda H, Graber M: Pseudopulmonary embolism: acute respiratory distress in the syndrome of heparin-induced thrombocytopenia. Am J Kidney Dis 1997;29:449–452.
3.
Kamper AM, Lins RL, Zachee P, Van Bergen S, Hosten S, Daelemans R: Safety of combining ticlopidine with nadroparin in the routine treatment of chronic hemodialysis patients. Nephron 1997;77:484–485.
4.
Warkentin TE, Heddle NM: Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003;2:148–157.
5.
Warkentin TE: Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia: recommendation of the College of American Pathologists. Arch Pathol Lab Med 2002;126:1415–1423.
6.
Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG: Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703–1708.
7.
Amiral J, Wolf M, Fischer AM, Boyer-Neumann C, Meyer D: Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thombocytopenia. Br J Haematol 1996;92:945–949.
8.
Reilly RF: The pathophysiology of immune-mediated heparin-induced thrombocytopenia. Semin Dial 2003;16:54–60.
9.
Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T: Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis 1996;28:82–85.
10.
Greinacher A, Zinn S, Wizemann S, Birk UW: Heparin-induced antibodies as a risk factor for thromboembolism and haemorrhage in patients undergoing chronic haemodialysis. Lancet 1996;348:764.
11.
Sitter T, Spannagl M, Banas B, Schiff H: Prevalence of heparin-induced PF4-heparin antibodies in hemodialysis patients. Nephron 1998;79:245–246.
12.
Luzzatto G, Bertoli M, Cella G, Fabris F, Zaia B, Girolami A: Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis. Thromb Res 1998;89:115–122.
13.
Boon DM, van Vliet HH, Zietse R, Kappers-Klunne MC: The presence of antibodies against a PF4-heparin complex in patients on haemodialysis. Thromb Haemost 1996;76:480.
14.
O’Shea SI, Sands JJ, Nudo SA, Ortel TL: Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. Am J HematoI 2002;69:72–73.
15.
O’Shea SI, Ortel TL, Kovalik EC: Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Semin Dial 2003;16:61–67.
16.
Tejedor Alonso MA, Lopez Revuelta K: Thrombocytopenia and anaphylaxis secondary to heparin in a hemodialysis patient. Clin Nephrol 2005;63:236–240.
17.
Warkentin TE: An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost 2004;30:271–283.
18.
Fretschner R, Dietrich K, Unertl K, Greinacher A: Management of liver transplantation in a patient with a history of heparin-induced thrombocytopenia. Transpl Int 2005;18:664–667.
19.
Lee DH, Warkentin TE: Frequency of heparin-induced thrombocytopenia; in Warkentin, TE Greinacher A (eds): Heparin-Induced Thrombocytopenia, ed 2. New York, Dekker, 2001.
20.
Potzsch B, Klovekorn WP, Madlener K: Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000;343:173.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.